- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01502501
Safety and Efficacy of Adipose Derived Stem Cells for Non-Ischemic Congestive Heart Failure
July 19, 2017 updated by: Ageless Regenerative Institute
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Intramyocardial and Intravenous Implantation of Autologous Adipose-Derived Stem Cells in Non-Ischemic Congestive Heart Failure Patients
The intent of this clinical study is to answer the questions:
- Is the proposed treatment safe
- Is treatment effective in improving the disease pathology of patients with Heart Disease as assessed by a series of measurements indicating improvement, stability, or degradation of a patient's cardiovascular function and exercise capacity?
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This will be an open-label, non-randomized, multi-center patient-sponsored study designed to assess the safety and cardiovascular effects of Adipose-derived Stem Cell (ASC) implantation using a catheter delivery system in patients who have nonischemic congestive heart failure.
A percutaneous transluminal endomyocardial injection catheter will be used for delivery of ASCs.
The therapy is composed of cells isolated from a patient's own adipose tissue.
Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Baja California
-
Tijuana, Baja California, Mexico, 22010
- Instituto de Medicina Regenerativa
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to sign informed consent
- Age >18 years and < 80 years
- NYHA Class II-IV
- Congestive Heart Failure without an acute coronary syndrome during the prior 6 months
LVEF less than or equal to 40% measured by echocardiography at both local and investigative sites, AND
- Left ventricular wall without mural thrombus and of thickness greater than 0.5 cm
- No significant valvular disease including: Moderate-to-severe mitral regurgitation (3-4+), aorticstenosis (valve area <1.5 cm2), aortic insufficiency (3-4+)
- Up to date on all age and gender appropriate cancer screening per American Cancer Society
Exclusion Criteria:
- Limiting symptoms due to non-CHF causes, such as lung disease, peripheral vascular disease, arthritis or other musculoskeletal disorders
- Inability to complete a 6-minute walk test for any reason
- Need for intravenous CHF medications, chronic continuous oxygen therapy or oral steroids,
- Coronary Artery Bypass Surgery (CABG) surgery within 60 days prior to screening
- Planned revascularization within 4 months following enrollment
- Aortic aneurysm or dilatation (>3.8 cm by echocardiography or other imaging modality)
- Peripheral vascular disease at or below the distal aorta that may interfere with catheter use
- Hemodynamically significant pericardial disease
- Prior aortic or mitral valve replacement
- Biventricular pacing device implant within the last 3 months OR whose device is scheduled to be revised following enrollment in this trial
- Scheduled to receive or history of cardiac transplant, surgical remodeling procedure, left ventricular assist device
- Stroke within 180 days of screening
- Positive pregnancy test in women of child bearing potential or who are unwilling to use an acceptable method of contraception.
- Drug or alcohol dependence
- Life expectancy of less than 1 year
- History of cancer (other than non-melanoma skin cancer or in situ cervical cancer) in the last five years
- Exposure to angiogenic therapy (including myocardial laser) or another investigational drug within 60 days of screening, or enrollment in any concurrent study that may confound the results of this study
- Any factors in the opinion of the Investigator which render the patient unsuitable for participation, that will interfere with conduct of the study or interpretation of the results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in 6 minute walk test
Time Frame: 3 months
|
compared to baseline
|
3 months
|
Minnesota Living with Heart Failure Quality of Life Questionnaire
Time Frame: 3 months
|
3 months
|
|
Improvement in 6 minute walk test
Time Frame: 6 months
|
6 months
|
|
Minnesota Living with Heart Failure Quality of Life Questionnaire
Time Frame: 6 months
|
6 months
|
|
Number of Adverse Events
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in New York Heart Association (NYHA) classification
Time Frame: 3 months
|
3 months
|
|
Improvement in the Left Ventricular Ejection Fraction (LVEF)
Time Frame: 3 months
|
Determined by and echo
|
3 months
|
Improvement in the Left Ventricular (LV) Volume
Time Frame: 3 months
|
Determined by an echo
|
3 months
|
Improvement in New York Heart Association (NYHA) classification
Time Frame: 6 months
|
6 months
|
|
Improvement in the Left Ventricular Ejection Fraction (LVEF)
Time Frame: 6 months
|
6 months
|
|
Improvement in the Left Ventricular (LV) Volume
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Juan J Parcero, MD, Instituto de Medicina Regenerativa
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Anticipated)
December 1, 2014
Study Completion (Anticipated)
June 1, 2015
Study Registration Dates
First Submitted
December 27, 2011
First Submitted That Met QC Criteria
December 29, 2011
First Posted (Estimate)
December 30, 2011
Study Record Updates
Last Update Posted (Actual)
July 21, 2017
Last Update Submitted That Met QC Criteria
July 19, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADI-ME-CHF-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Ischemic Congestive Heart Failure
-
Assistance Publique - Hôpitaux de ParisCelladon CorporationTerminatedIschemic Cardiomyopathy | Non-ischemic Cardiomyopathy | Heart Failure CongestiveFrance
-
University of Texas Southwestern Medical CenterWithdrawnCongestive Heart Failure | Non-ischemic CardiomyopathyUnited States
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawnIschemic Congestive Heart FailureMexico
-
Rajaie Cardiovascular Medical and Research CenterUnknownHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Ischemic Cardiomyopathy | Heart Rate Low | Heart Failure,Congestive | CT Angiography | Non-ischemic CardiomyopathyIran, Islamic Republic of
-
Asklepios Biopharmaceutical, Inc.RecruitingCardiovascular Diseases | Heart Failure | Heart Failure, Diastolic | Congestive Heart Failure | Heart Failure, Systolic | Heart Disease, Ischemic | Heart Failure,Congestive | Heart Arrhythmia | Heart; ComplicationsUnited States
-
Losordo, Douglas, M.D.WithdrawnIschemic Congestive Heart Failure (CHF)
-
Naofumi TakeharaNational Cerebral and Cardiovascular Center; Translational Research Center... and other collaboratorsCompletedVentricular Dysfunction | Congestive Heart Failure | Ischemic CardiomyopathyJapan
-
Ann Marie ChikowskiMain Line HealthCompletedDilated Cardiomyopathy | Congestive Heart Failure | Ischemic Congestive CardiomyopathyUnited States
-
Phoenix VA Health Care SystemCompletedCongestive Heart Failure | Ischemic CardiomyopathyUnited States
-
Seattle Institute for Cardiac ResearchNational Institutes of Health (NIH); Abbott Medical DevicesUnknownCongestive Heart Failure | Left Ventricular Systolic Dysfunction | Ischemic and Non-ischemic Cardiomyopathy | Sudden Cardiac Death Primary PreventionUnited States
Clinical Trials on Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)
-
Ageless Regenerative InstituteWithdrawnParkinson's DiseaseUnited States
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawnIschemic Congestive Heart FailureMexico
-
Rigshospitalet, DenmarkActive, not recruitingKeratoconjunctivitis Sicca, in Sjogren's SyndromeDenmark
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawnBrain Lesion (General)Mexico
-
University Hospital, ToulouseCentre National de la Recherche Scientifique, France; French Blood Establishment and other collaboratorsCompletedCardiovascular Diseases | Peripheral Vascular DiseasesFrance
-
A.A. Partners, LLCUnknownSecond- or Third-degree BurnsUkraine
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawn
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawn
-
Instituto de Investigación Hospital Universitario...UnknownRecto-vaginal FistulaSpain
-
University of Science Ho Chi Minh CityVan Hanh General Hospital; Nguyen Tri Phuong Hospital, Ho Chi Minh city, Viet... and other collaboratorsUnknown